Dislog Group continues its expansion in the medical sector by signing a memorandum of understanding to acquire 70% of the shares in Afrobiomedic, a key player in the field of implantable cardiology devices in Morocco. This move is part of the group's external growth strategy (M&A) and aims to strengthen its healthcare division. Founded in 2009, Afrobiomedic specializes in the import and distribution of medical devices for interventional cardiology, structural cardiology, and electrophysiology, with a presence also in vascular interventional neuroradiology. The company benefits from exclusive partnerships with international brands and offers cutting-edge equipment certified to ISO 13485 standards, thereby ensuring high quality for Moroccan healthcare professionals. Driss Nasr, founder and sole shareholder of Afrobiomedic, will retain 30% of the capital and will continue to lead the company to drive its development in Morocco and Africa. This partnership with Dislog Group will accelerate Afrobiomedic's growth by leveraging the synergies and industrial capabilities of the group. Dislog Group, already well-established in the pharmaceutical industry and medical devices, thus strengthens its healthcare division, which includes several specialized entities such as Megaflex, Kosmopharm, Steripharma, Somapharma, Africare, and Dislog Santé. This division is structured around three business units covering the pharmaceutical industry, medical devices, and dermo-cosmetics, creating a complete value chain from drug manufacturing to the distribution of specialized equipment. This transaction remains subject to approval by the Competition Council.
